Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | The role of risvodetinib in the treatment of Parkinson’s disease & other CNS diseases

Milton Werner, PhD, Inhibikase Therapeutics, Inc., Atlanta, GA, discusses the role of risvodetinib in the treatment landscape of Parkinson’s disease. While several medications are in clinical development for disease modification, only a few ideas show promise, and risvodetinib is one of them. Currently, Parkinson’s disease is their primary focus due to its objective measures, such as analyzing how a person walks and moves. However, if they see clinical benefits of risvodetinib in Parkinson’s disease, it could potentially apply to other CNS diseases like Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and Huntington’s disease. This transformation in tackling major CNS diseases could pave the way for new treatments and improvement in patient care. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Milton Werner reports the following disclosures:
Founder and largest shareholder, Inhibikase Therapeutics, Inc.